100.30EUR-3.00%Mkt Cap: —P/E: —1d ago
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value8.39B $
Revenue (TTM)5.35M $
Gross Profit5.35M $
Net Income (TTM)-361.09M $
Revenue/Share0.0728 USD
Last Price100.30 EUR
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees80
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINFR0012333284
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-30.38
EV/Revenue1568.61
P/S—
P/B19.03
EPS (TTM)-2.47
EPS (Forward)—
52W Range
100.006% of range105.40
52W High105.40 EUR
52W Low100.00 EUR
Profitability
Gross Margin100.00%
Oper. Margin-4183.70%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-157.07%
ROA-44.65%
Growth
Revenue Growth35.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-193.88M $
CapEx (TTM)—
FCF Margin-2326.66%
FCF Yield—
Net Debt-497.11M $
Net Debt/EBITDA1.80
Balance Sheet
Debt/Equity7.96
Current Ratio8.25
Quick Ratio8.07
Book Value/Sh5.418 EUR
Cash/Share6.199 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.9.98M
Float69.36M
Insiders4.85%
Institutions48.04%
Technical
SMA 5011.44 (+776.7%)
SMA 20013.25 (+657.3%)
Beta-0.23
S&P 52W Chg20.80%
Avg Vol (30d)853
Avg Vol (10d)1.84K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—